{"id":"W4403239841","doi":"10.1136/ijgc-2024-005919","title":"GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Verastem Oncology; GOG Foundation; Australia New Zealand Gynaecological Oncology Group; GlaxoSmithKline; AstraZeneca","keywords":"Medicine; Ovarian cancer; Serous fluid; Regimen; Oncology; Internal medicine; Discontinuation; KRAS; Tolerability; Clinical trial; Clinical endpoint; Progression-free survival; Adverse effect; Cancer; Chemotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002539737,0.001533681,0.00211053,0.0004516791,0.0004635113,0.001014858,0.0009790345,0.002209185,0.008281203],"category_scores_gemma":[0.001904774,0.0005409932,0.002095411,0.0004314871,0.001140789,0.001276696,0.0004167984,0.003599828,0.001275781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009642793,"about_ca_system_score_gemma":0.001393168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008919793,"about_ca_topic_score_gemma":0.002825661,"domain_scores_codex":[0.9990915,0.0005305089,0.00004493527,0.0001429752,0.00007032288,0.0001199055],"domain_scores_gemma":[0.9988616,0.0003263053,0.0003249671,0.00006123388,0.00006788905,0.0003580482],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9708226,0.006152231,0.0008381265,0.0009366094,0.0007094859,0.00004590399,0.00005268583,0.0003318628,0.002098738,0.0001614299,0.001744094,0.01610636],"study_design_scores_gemma":[0.9194142,0.07692915,0.001494137,0.00004958107,0.0003578225,0.00005977289,0.00002179441,0.0004479065,0.0002575061,0.0001635976,0.000789953,0.00001458298],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9739526,0.007328972,0.000645636,0.001639237,0.0006782565,0.008632321,0.002303258,0.0002946626,0.004525085],"genre_scores_gemma":[0.9817801,0.002408851,0.001568866,0.002079464,0.0004348148,0.006776866,0.002046805,0.00004396574,0.002860289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008281203,"threshold_uncertainty_score":0.0277034,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07159507315498903,"score_gpt":0.4099690937908886,"score_spread":0.3383740206358996,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}